Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Trilaciclib in Neoadjuvant Osteosarcoma
NCT06714383Phase 2Recruiting
- Sponsor
- Peking University People's Hospital
- Start
- Nov 2024
- Primary completion
- Jul 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of trilaciclib in osteosarcoma (OS), sponsored by Peking University People's Hospital. Started Nov 2024; status: recruiting.
02
Drugs
trilaciclib
03
Conditions
osteosarcoma (OS)
Beyond the preview
Go deeper on NCT06714383.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06714383.